Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
On careful examination the actual cost to TEVA is 2.3 Billion (10% cost of goods) over 10 years.
The article heading is different from the detail. The latter is more believable and is a positive signal.
https://www.biopharmadive.com/news/teva-opioid-settlement-offer-23-billion-suboxone/565493/
This transaction may signal a basement price....fill up time.
There were five director purchases during August 2019 around the 60p mark. This suggests internal confidence and commitment going forward.....
Back in again...
Got a few myself yesterday and today.........
Along with patience may also be an opportunity to top up if funds available...
No I'm waiting for sure, not selling at all. Just a bit too quiet in here. Unfortunately I do have to rely on others for any news given my work schedule. Last week there were encouraging posts but this week silence, that's all. The market in general is a bit soft this week but I am definitely waiting for an upturn on news.
Terribly quiet in here amidst a sea of red! Walking wounded. The same could be said for a number of other stocks which were touted to explode......not good...
Sorry for the typo....mi glasses now are failing me...just as well. I should now just take something and sleep till Monday...jeez.
Whete/who did the date come from in the first place? Ruined my weekend!
..but we still moan....oh dear. The only reason to sell would be for cash flow purposes. Otherwise it seems to me that the company is on the right track and it's only a matter of time.
should do well. Good to hear about new contracts etc.
ARK THERAPEUTICS GROUP PLC Ark Therapeutics signs manufacturing agreement with University of Glasgow London, UK - 3 November 2011, Ark Therapeutics Group plc ("Ark") is pleased to announce that it has signed a manufacturing agreement with University of Glasgow's Institute of Cardiovascular and Medical Sciences under which Ark will provide full manufacturing and related services to support the development of the Institute's gene-therapy programme for the treatment of vein graft failure associated with coronary artery bypass surgery. The contract was awarded following Ark's success in an open competitive tender process under public body procurement rules. Ark will manufacture for University of Glasgow cGMP grade adenoviral vector expressing TIMP3 gene to be administered ex vivo to vein grafts at the time of coronary artery bypass surgery in the University's first-in-man Phase I/II trial to reduce vein graft failure. Financial details of the agreement were not disclosed. Martyn Williams, CEO of Ark commented: "We are delighted to announce this agreement with the University of Glasgow for their highly innovative gene-therapy programme in heart bypass surgery. Our success in this competitive tender exercise further demonstrates that Ark is establishing itself as a leading provider of viral manufacturing services utilising our world leading expertise in this arena." Professor Anna Dominiczak, Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow, said: "This research, to prevent vein graft failure, is a very important development. It is crucial that we work with an experienced company for provision of clinical grade reagents for our clinical trial, which if successful will make a substantial difference to the long-term success of heart bypass procedures."
Good stuff.....thanks for that
Company seems to be making the right moves....just need to secure some pertinent legislation.
An impressive number of buys all day...may be time for lift off...
Strong buying at the asking price....some thing's brewing in plastic.....
Good to see some buying at the ask price.